Taysha Gene Therapies, Inc. (TSHA)

In the past six months, Taysha reported its first-quarter 2026 financial results, including a net loss of $42.4 million, but reaffirmed FDA alignment on a BLA pathway for TSHA-102 and stated that its cash resources are expected to fund planned operating expenses into 2028. The company presented preclinical data at ASGCT, demonstrating that TSHA-102's scAAV9 construct delivers approximately 30-fold higher MeCP2 expression compared to ssAAV9. Taysha reported full-year 2025 financial results, highlighting significant execution in 2025, including dosing multiple Rett syndrome patients in the REVEAL pivotal trial and FDA clearance to initiate the ASPIRE trial. News related to options trading was reported in February and November 2026. Chardan Capital and Citizens maintained positive recommendations for Taysha Gene Therapies, and Fintel reported an increase in Taysha Gene Therapies' price target. The FDA granted Breakthrough Therapy designation to TSHA-102 for Rett syndrome and finalized alignment on the REVEAL pivotal trial protocol.

The demand for Taysha Gene Therapies' products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the prevalence of specific diseases, the successful progression of its clinical trials, and regulatory approvals and market access. Demand is tied to patient identification and treatment initiation rather than recurring seasonal patterns.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing AAV-based gene therapies for severe monogenic CNS diseases, targeting both rare and larger patient populations. Its lead clinical program, TSHA-102, is in clinical evaluation for Rett syndrome and utilizes miRARE technology to regulate MECP2 expression. Other product candidates include TSHA-120 for GAN, TSHA-121 for CLN7 disease, TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 deficiency, TSHA-113 for tauopathies, TSHA-106 for Angelman syndrome, and TSHA-114 for Fragile X syndrome.

Taysha Gene Therapies, Inc. is headquartered in Dallas, Texas, and has a laboratory facility in Durham, North Carolina. The company planned a commercial-scale cGMP gene therapy manufacturing facility in Durham, North Carolina, with production expected to begin in 2023. Taysha targets major markets like the U.S. and Europe with its regulatory strategies and conducts clinical trials at international sites. They also have a manufacturing partnership with Catalent, which has gene therapy facilities in the U.S. and Europe.

Taysha Gene Therapies' brand reputation over the past year appears to be largely positive, driven by significant progress in its clinical programs and favorable regulatory interactions. The FDA granted Breakthrough Therapy designation to TSHA-102 for Rett syndrome. Consistent reporting of positive safety and preliminary efficacy data from clinical trials for TSHA-102 has contributed to a strong scientific and clinical reputation. Taysha has maintained constructive dialogue and achieved alignment with the FDA on the BLA pathway for TSHA-102. Reports indicating a cash runway into 2028 suggest financial prudence and stability. The presentation of preclinical data in April 2026, showing superior MeCP2 expression with TSHA-102, further reinforced the scientific foundation and potential of their lead program.

Taysha Gene Therapies, Inc. has a diverse ownership structure, including institutional, insider, and retail investors. As of May 7, 2026, there were 200 institutional owners holding a total of 281,337,230 shares, with Ra Capital Management, L.p., Avoro Capital Advisors LLC, and BlackRock, Inc. being the largest shareholders. Insiders own approximately 12.22% of the company's stock, with key individual owners including Paul B Manning, RA Session II, Sean P Nolan, Kamran Alam, and Sukumar Nagendran. RA Session II is the largest individual shareholder, owning 9.01 million shares, representing 3.14% of the company.